Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | LPL | P06858 | 4/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL586676 | 0.79 | KDM4E (0.53) | MAPTKDM4EALDH1A1LPLLIPG | |
| SCHEMBL25222911 | 0.78 | MEN1 (0.39) | MAPTKDM4EGAALMNAALDH1A1 | |
| SCHEMBL16277720 | 0.78 | MAPT (0.61) | MAPTALDH1A1KMT2AHTTMEN1 | |
| SCHEMBL25409382 | 0.78 | GAA (0.49) | MAPTKDM4EGAALMNAALDH1A1 | |
| SCHEMBL23551417 | 0.76 | MAPT (0.42) | MAPTKDM4EGAALMNAALDH1A1 | |
| SCHEMBL20548927 | 0.76 | DRD2 (0.40) | MAPTKDM4EALDH1A1KMT2ALPL | |
| SCHEMBL15656543 | 0.76 | MAPT (0.48) | MAPTKDM4EGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL16669607 | 0.76 | MAPT (0.42) | MAPTKDM4EGAALMNAALDH1A1 | |
| SCHEMBL24979321 | 0.76 | SMN1; SMN2 (0.46) | MAPTKDM4EGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL21296301 | 0.74 | MAPT (0.49) | MAPTKDM4EGAALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570650-B2 | 6-substituted pyridazine compounds as SMARCA2 and/or SMARCA4 degraders | AURIGENE ONCOLOGY LIMITED (IN) | 2026-03-10 | — | — | US | disclosed |
| US-20240018134-A1 | 6-Substituted Pyridazine Compounds as SMARCA2 and/or SMARCA4 Degraders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2024-01-18 | — | — | US | disclosed |
| EP-4192835-A1 | 6-SUBSTITUTED PYRIDAZINE COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS | Aurigene Oncology Limited (IN) | 2023-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018134-A1 | 6-Substituted Pyridazine Compounds as SMARCA2 and/or SMARCA4 Degraders | SMARCC1, SMARCC2, SMARCA4 | MAPT 1290/4885KDM4E 363/4885GAA 1001/4885 |
| US-12570650-B2 | 6-substituted pyridazine compounds as SMARCA2 and/or SMARCA4 degraders | SMARCC1, SMARCC2, SMARCA1 | MAPT 3389/4885KDM4E 784/4885GAA 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.